TLR2 activation for instance, has been suggested as a possible therapeutic target, with local administration of a TLR2/6 agonist resulting in reduced tumor growth and prolonged survival in a pancreatic carcinoma mouse model (178). This evidence concerns the gene TLR2 and neoplasm.